Table 2.
Development in vitro and in vivo (two-cell transfer) of SCNT-derived embryos treated with HDAC inhibitors
| HDAC inhibitor | Concentration of inhibitor (nM) | No. of embryos cultured | No. (%) of two-cell embryos at 24 h | No. of embryos transferred (no. of recipients) | No. of implantations (%) | No. of offspring (%) | No. of placentas only (%) |
|---|---|---|---|---|---|---|---|
| Control | – | 487 | 416 (85.4) | 213 (8) | 93 (43.7) | 6 (2.8) | 6 (2.8) |
| TSA | 5 | 153 | 133 (86.9) | 109 (6) | 69 (63.3)* | 8 (7.3) | 3 (2.8) |
| Ky-2 | 100 | 153 | 142 (92.8)* | 137 (6) | 55 (40.1) | 3 (2.2) | 3 (2.2) |
| 10 | 74 | 68 (91.9) | 73 (4) | 40 (54.8) | 1 (1.4) | 3 (4.1) | |
| Ky-9 | 3200 | 232 | 203 (87.5) | 135 (6) | 78 (57.8)* | 9 (6.7) | 2 (1.5) |
| 1600 | 196 | 179 (91.3)* | 139 (7) | 74 (53.2)* | 10 (7.2)* | 4 (2.9) | |
| 320 | NR | NR | 194 (6) | 103 (53.1)* | 9 (4.6) | 3 (1.5) | |
| 32 | 71 | 60 (84.5) | 69 (4) | 39 (56.5)* | 2 (2.9) | 3 (4.3) | |
| Ky-29 | 2000 | 335 | 292 (87.2) | 217 (9) | 85 (39.2) | 3 (1.4) | 3 (1.4) |
| 400 | 228 | 203 (89.0) | 181 (9) | 116 (64.1)* | 6 (3.3) | 2 (1.1) | |
| Ky-72 | 1600 | 113 | 105 (92.9)* | 85 (3) | 36 (42.4) | 2 (2.4) | 1 (1.2) |
| Ky-309 | 5 | 73 | 66 (90.4) | 66 (4) | 33 (50.0) | 1 (1.5) | 2 (3.0) |
| 1 | 247 | 190 (76.9)* | 68 (4) | 21 (30.9)* | 0 (0) | 0 (0) | |
| 0.5 | 288 | 251 (87.2) | 84 (3) | 32 (38.1) | 1 (1.2) | 0 (0) |
NR, not recorded.
* P < 0.05 (vs. control, Fisher exact probability test).